INTRODUCTION
Tuberous sclerosis complex (TSC) is a genetic disorder that is characterized by development of hamartomas, which can arise in multiple organs, including brain, kidney, skin and liver. TSC is linked to mutations in either the TSC1 or TSC2 gene, which encode the proteins hamartin and tuberin, respectively. These two proteins form a complex and function as a GTPase activating protein upon the small GTPase Rheb, which is required for the activation of mammalian target of rapamycin complex 1 (mTORC1). mTORC1 plays a pivotal role in controlling cell growth, in part by promoting protein translation through its downstream effectors, ribosomal S6 kinase and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) (1, 2) . It has been shown that mTORC1 responds to various extra-and intra-cellular signals, including growth factors, nutrients, energy status and oxygen levels, via different upstream regulatory pathways (2, 3) . One upstream pathway that regulates mTORC1 is the phosphotidylinositol 3-kinase (PI3K)/AKT pathway, which responds to extracellular signals via either receptor tyrosine kinases or G-protein coupled receptors (4) . Upon activation, PI3K phosphorylates phosphotidylinosital-4,5-biphosphate (PIP2) to phosphotidylinosital-3,4,5-triphosphate (PIP3), resulting in the accumulation of PIP3 at the plasma membrane. Generation of PIP3 in turn leads to the recruitment of AKT to the plasma membrane, and further AKT activation. AKT directly phosphorylates TSC2, leading to the accumulation of active GTP-bound Rheb and subsequent mTORC1 activation (5-7). A critical negative regulator of this pathway is PTEN (Phosphatase and tensin homolog deleted on chromosome 10), a lipid phosphatase that dephosphorylates PIP3 to PIP2, directly counteracting the kinase function of PI3K. Thus, PTEN and TSC1/2 can function in concert to negatively regulate mTORC1 activity.
Humans and rodents with loss of either TSC1 or TSC2 are prone to developing renal problems including renal cysts (8) (9) (10) . Renal cysts in TSC patients typically appear with limited size and number, and normally do not interfere with renal function. However, a small but well documented percentage of TSC patients do present with severe infantile polycystic kidney disease (PKD), which, unlike the renal cyst development observed in most TSC patients, is characterized by the presence of numerous cysts in the kidney and usually leads to renal failure (11) (12) (13) (14) . This phenomenon has been primarily attributed to the fact that the TSC2 gene is in close proximity to the PKD1 gene on chromosome 16 . Mutation of the PKD1 gene is genetically linked to PKD in humans (15) . Clinically, severe infantile PKD cases found in TSC patients are associated with deletions on chromosome 16 that affect both genes (16, 17) .
However, recent advances in the field have implicated the functional involvement of the TSC/mTORC1 pathway in PKD. First, Kleymenova et al. (18) have observed severe PKD cases in a small percentage of Eker rats, the rat strain that harbors mutation on one Tsc2 allele due to a spontaneous insertion. They further established a cell line from the cyst-lining cells of an affected polycystic kidney, and revealed loss of the second functional Tsc2 allele but intact Pkd1 gene expression. In these cells, membrane localization of polycystin-1 protein, the product of the Pkd1 locus, was absent, suggesting that TSC2 is required for proper cellular localization of polycystin-1. Second, Traykova-Brauch et al. (19) recently reported that conditional knockout of Tsc1 in renal tubular cells resulted in PKD. However, how loss of Tsc1 induced PKD in this murine model was not further investigated. Furthermore, Shillingford et al. (20) reported elevated mTORC1 activity in cyst-lining cells of human and mouse PKD samples and further demonstrated that the mTORC1 inhibitor, rapamycin, effectively reduced cyst development in mouse models of PKD, suggesting that mTORC1 is regulated by Polycystin-1 and involved in cystogenesis. These data indicate that dysregulation of the TSC/mTORC1 pathway may play a role in PKD. However, despite these interesting findings, direct evidence that elevated mTORC1 activity induces PKD is lacking. Therefore, it is still not clear whether the elevated mTORC1 activity observed in PKD samples is a causal or ancillary effect of cyst formation.
In this study, we describe a new PKD mouse model generated by conditional deletion of the Tsc1 gene in a subset of renal tubular cells. These mice develop extensive cysts during early postnatal stages that resemble severe infantile PKD cases reported to harbor contiguous deletions of both the TSC2 and PKD1 genes. Examination of the renal tubular cells reveals that cyst development is closely correlated with elevated mTORC1 activity, leading to cellular hypertrophy and increased proliferation of the renal tubular cells. Furthermore, we demonstrate that inhibition of mTORC1 activity with low dosage of rapamycin can effectively block cyst formation and control cyst development, indicating that cyst formation is extremely sensitive to the level of mTORC1 activity. Additionally, we report that loss of Pten in the same context does not result in development of PKD due to limited activation of mTORC1 in early postnatal stages, although Pten and Tsc1 double-knockout mice develop severe PKD. These data suggest that PTEN is not a major upstream regulator of TSC/mTORC1 in the kidney during early postnatal development.
RESULTS

Tsc1 mutant mice have increased mortality and develop severe PKD
We previously generated an Nse-cre mouse line with Cre gene expression driven by the promoter of the rat neuron-specific enolase gene (Nse). We demonstrated that Cre activity is present mainly in subsets of post-mitotic neurons in the brain, as well as in a limited number of cells in the kidney and testis (21) . We generated Tsc1 conditional knockout mice (Tsc1 mutant mice hereafter) by crossing Tsc1 loxP mice (22) with this Nse-cre line, initially aiming to assess the function of the TSC/mTORC1 pathway in the nervous system. Surprisingly, the Tsc1 mutant mice, though appearing normal at birth, soon became distinguishable from their littermates by a notably smaller body size and a distended abdomen (Fig. 1A and B) . In addition, the mutant mice had increased mortality starting from 3 to 4 weeks of age and most died before adulthood (Fig. 1C) . This was surprising, since the Cre expression in brain, which only targets limited brain regions, starts gradually at postnatal stages and is not fully activated until 4 weeks of age (21, 23) . Further examination revealed that Tsc1 mutant mice had severe polycystic kidneys ( Fig. 1D and E). The phenotype was fully penetrant and always appeared bilaterally, although there were variations in terms of the extent of cyst development. Further, the cysts formed mainly in the cortex, with most of the medulla remaining intact (Fig. 1E ). This massive renal cyst formation was accompanied by dramatically increased levels of blood urea nitrogen (BUN) by 4 weeks of age, suggesting that the premature death may be caused by renal failure (Fig. 1F ).
Nse-cre activity in the kidney is restricted to a subset of cells of the nephron
We suspected that the development of PKD in Tsc1 mutant mice was due to the ectopic expression of the Nse-cre line in the kidney that was verified for Cre-mediated recombination of Tsc1 alleles using PCR (Supplementary Material, Fig. S1 ). To identify the specific cells in which Cre became active in the kidney, we crossed the Rosa26-stop-lacZ and Rosa26-stop-YFP reporter lines with the Nse-cre line (24, 25) . As demonstrated by X-gal staining, Cre activity was largely restricted to the cortex in fully developed kidneys Fig. S2C ). During the early stages of metanephric kidney formation, Cre activity was detected initially in mesenchymal blastema cells and later in the newly-formed nephrons (comma or S-shaped bodies), but was not observed in the ureteric buds, which give rise to the collecting ducts. These data are consistent with the Cre activity pattern in the fully developed kidney. We suspect that this unique and ectopic Cre expression pattern may be the result of the combinatorial effects of the Nse promoter and chromosomal position effects on the transgene.
Tsc1 mutant mice develop severe polycystic kidneys postnatally
To get a clear view of cyst development, we examined kidneys of Tsc1 mutant mice at different time points. We found that at P0, kidneys from Tsc1 mutants were anatomically normal, though slightly enlarged ( Fig. 2A) . Thus, Tsc1 loss in a subset of renal tubular cells did not appreciably affect embryonic kidney development. However, renal cysts were usually evident by P7 in the inner cortex and surrounded by pinkcolored epithelial cells after H&E staining (Fig. 2B) . The proximal tubule-origin of these initial cysts was confirmed by LTA staining (Supplementary Material, Fig. S3A ). Cysts developed quickly in the following weeks with an increase in both size and number. By P14, cysts were widely distributed in the cortex, but restricted to renal tubules, leaving glomeruli largely intact ( (Fig. 2B ). This progressive cyst development resulted in a substantial increase in renal volume as reflected by substantial increased kidney weight during the first postnatal month (Fig. 2C ). In addition, along with cyst development, increased interstitial infiltration was observed, which appeared as early as P7 and filled almost all the space between cysts in the later stages (Fig. 2B , lower panels).
We also frequently observed cysts filled with multiple layers of epithelial cells that, in some cases, formed a tumor-like structure (Fig. 2D) . Under higher magnification, it was easy to identify mitotic figures in the tumor-like masses (Fig. 2D , arrows). In other cases, the epithelial cells accumulated along the edge of the cysts. Among those cells, we occasionally observed large vacuoles inside the cell that pushed the nuclei to the side (Fig. 2D, arrowheads) . These interesting features resembled some characteristics of human renal cell carcinoma. However, within the limited lifetime of these mutant mice, no frank invading tumors were ever observed. It is likely that the dramatic cyst formation was responsible for causing renal failure, resulting in the early demise of the mice and thus leaving no time for tumor progression. 
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Loss of Tsc1 in a subset of renal tubular cells results in general activation of mTORC1
We evaluated mTORC1 activity in the mutant kidneys by examining the phosphorylation status of two downstream effectors, the S6 ribosomal protein and the eukaryotic initiation factor 4EBP1. We first assessed phospho-S6 (Ser235/236) (P-S6, hereafter) levels by immunostaining. We observed an overall increase of P-S6 signal in the renal cortex of Tsc1 mutants (Fig. 3A) . At P7, although some P-S6 signal was detected in the control kidneys, the mutants show much stronger and broader P-S6 staining, particularly in the inner cortex, where the initial cysts were observed. Under higher magnification, elevated P-S6 staining was clearly seen in the epithelial cells that surround those initial cysts (Fig. 3A , lower left panels). At P14, only minimal P-S6 staining was observed in the controls, whereas P-S6 staining in the mutants was even stronger, with almost all the cyst-lining cells showing elevated P-S6 staining. This result was consistent with western blotting analysis; using cell lysate from whole kidneys of either controls or mutants, we found that increased P-S6 and phospho-4EBP1 (Thr 37/46) (P-4EBP1, hereafter) levels in the mutants could be detected as early as P0 and intensified at P7 (Fig. 3B) .
Considering the limited Cre activity in the kidney, we were surprised by the broadly elevated mTORC1 activity and cyst formation. Due to a lack of reliable anti-Tsc1 antibody for immunostaining, we could not directly assess the level of Tsc1 protein. Therefore, we again adopted the Rosa-stop-YFP or Rosa-stop-lacZ reporter lines to reflect Cre-mediated recombination in Tsc1 mutants. We focused primarily on the cyst-lining epithelial cells, since abnormalities of these cells are believed to be closely associated with cyst formation. Interestingly, not all cyst-lining cells were positive for X-gal staining: the cyst-lining cells in Nse-cre;Tsc1 loxP/loxP ; Rosa-stop-lacZ mice displayed a mosaic staining pattern, and as the cysts developed, more X-gal-negative cyst liningcells were detected (Fig. 4A ). This provided evidence that cysts were not solely composed of epithelial cells that had lost Tsc1. We next performed staining to evaluate mTORC1 activation in the cyst-lining cells. Although, we observed the expected coincidence of YFP and P-S6 double staining in Nsecre;Tsc1 loxP/loxP ;Rosa-stop-YFP mice, we also found some P-S6 stained cyst-lining cells that were YFP-negative. Thus, elevated mTORC1 activity was not restricted to tubular cells that had lost Tsc1 (Fig. 4B, arrowheads) . This broader elevated P-S6 level in contrast to the apparently more limited Cre activity raises the possibility that the increased mTORC1 activity in cyst-lining cells results from both cell autonomous and non-cell autonomous effects.
Cyst-lining cells with elevated mTORC1 activity demonstrate increased proliferation and abnormal morphology
Activation of mTORC1 is known to result in increased cell growth and proliferation in various cell types. We therefore examined cell proliferation in the kidneys of our Tsc1 mutant mice, using both BrdU (2 h pulse) and Ki67 labeling. Evidence of enhanced proliferation was limited at P7 but abundant along the cyst lining cells at P14 (Fig. 5) . These included examples of rapidly dividing cells piled up in the lumen, which explained the appearance of tumor-like structures. We also sought to determine whether there were abnormalities in cell death. Cell apoptosis was assessed by cleaved caspase 3 staining which showed no obvious increase in apoptosis in cyst-lining cells at P7 (Supplementary  Material, Fig. S4 ). However, as the cysts developed, sporadic apoptotic cells appeared within the lumen. This slight increase in apoptosis could be a side effect of cyst development, since overall, the apoptotic cells were few and appeared only in the later stages of cyst development.
To further evaluate possible effects on renal tubular cell morphology, we particularly focused on proximal tubules in the inner cortex, where the initial cysts were observed. ;Rosa-stop-YFP mice. Increased P-S6 staining is detected in both YFP-positive and YFP-negative cyst-lining cells (arrowheads). Scale bar, 100 mm.
At P7, many of the proximal tubular cells in the mutants were enlarged in comparison to control cells in comparable regions (Fig. 6A) . Some of the tubular cells were dramatically bigger, with enlarged nuclei (Fig. 6A, arrows) . The enlarged cell size was not due to cell mitosis, since those cells were negative for BrdU staining. This was also confirmed by LTA and Ki67 double staining (data not shown). Further, these enlarged tubular cells had elevated P-S6 levels, indicating high mTORC1 signaling (Fig. 6B) . The proximal tubular cells with high levels of P-S6 (Fig. 6B, asterisks) were enlarged compared with controls and to the nearby proximal tubular cells with negative P-S6 staining. This tubular cell hypertrophy was often accompanied by an enlarged lumen, indicating the development of renal cysts.
Rapamycin treatment inhibits cyst formation and controls cyst development
We reasoned that if the abnormal activation of mTORC1 was directly responsible for cyst formation, then the mTORC1-specific inhibitor, rapamycin, should inhibit cyst development. In vivo, rapamycin administration to block mTORC1 activity has been widely used in human and mouse. We found that high doses of rapamycin during early postnatal stages had severe adverse effects with the treated mice showing obvious growth retardation (data not shown). Therefore, we chose a relatively low rapamycin concentration for these experiments (2 mg/kg mouse bodyweight weekly). One group of mice were injected with a single dose of either rapamycin or vehicle at P7 and analyzed at P14. A single rapamycin administration was sufficient to inhibit cyst formation. The rapamycin-treated mutants ranged from reduced cyst formation to absence of obvious cysts (Fig. 7A) . In another group of mice, rapamycin was injected at P14, boosted at P21 and analyzed at P28. Therefore, in this group, rapamycin was applied when cysts were already present. Drug treatment did not eliminate the cysts but was effective in reducing both cyst size and number (Fig. 7B) . Quantification indicated that in both groups, rapamycin treatment dramatically inhibited enlargement of the kidney as reflected by kidney weight, but had no significant effect on body weight (Fig. 7C and D) .
Furthermore, mutant mice treated with rapamycin had reduced BUN levels, as compared with vehicle-treated controls (Fig. 7E) . However, these effects were dependent upon continued drug treatment; as in the first group, a single rapamycin injection at P7 was not sufficient to eliminate cyst formation indefinitely. If no additional rapamycin was applied, the mice eventually developed PKD (data not shown). Therefore, cyst formation and development in our mutant mice is largely dependent on continuous mTORC1 activity.
Loss of Pten in a similar context does not result in PKD due to limited activation of mTORC1
To further investigate the possible upstream regulators of TSC/mTORC1 in the cyst formation process, we examined the kidneys of Nse-cre;Pten loxp/loxp mice (Pten mutants hereafter). It has been well established that Pten loss results in activation of AKT, which leads to TSC1/2 complex inhibition and downstream activation of mTORC1. Unexpectedly, we did not see any obvious renal abnormalities in the Pten mutant mice, although Cre-mediated recombination of Pten alleles in the kidney was detected by PCR (Supplementary Material,  Fig. S5 ). The Pten mutant kidneys appeared histologically normal, although they did show a slight increase in size along with the growth of the mice, as quantified by a small increase in kidney weight at P28 (Fig. 8A and B) . No evidence of cyst formation was observed in Pten mutants analyzed at P28, consistent with the normal BUN levels observed in a larger group of Pten mutants (Fig. 8C ). This observation is consistent with a recent study on another Pten conditional knockout mouse line, indicating that loss of Pten alone in renal tubular cells is not sufficient to cause PKD (26) .
We next carefully evaluated mTORC1 activation downstream of Pten or Tsc1 mutation. We found that unlike loss of Tsc1, loss of Pten did not effectively promote early mTORC1 activation (Fig. 8D) . In Pten mutants, although Cre activity was only present in a subset of renal tubular cells, we detected a slightly decreased PTEN level and a trend of increase in P-AKT (Ser 473) level when examining whole kidney lysate, consistent with loss of Pten alleles in some renal cells (Fig. 8D) . However, there was no evidence of increase in P-4EBP1 levels, and only a trend of increasing P-S6 levels. Further, the increased P-S6 level in Pten mutants was low, as directly compared with Tsc1 mutants (Fig. 8D) . The minimal activation of mTORC1 activity in Pten mutants was further confirmed by immunostaining. At P7, Pten mutant kidneys showed normal level of P-S6 staining in the inner cortex (Fig. 8E , upper panels) and evidence of increased P-S6 staining in Pten mutants was not observed until P28 (Fig. 8E, lower panels) . Thus, loss of Pten, as driven by Nse-Cre, did not result in a high level of mTORC1 activation. At the same time, we also considered that the TSC complex is only one of several AKT downstream pathways. It was therefore possible that other AKT downstream pathways compromised mTORC1 activity and inhibited cyst formation. However, this possibility was excluded by the fact that double mutant mice (Nse-cre;Pten loxP/loxP ;Tsc1 loxP/loxP ) developed PKD, and had more severe postnatal lethality than Tsc1 single mutants (Fig. 9A) . In the same breeding, we observed that Nse-cre;Pten loxP/loxP ;Tsc1 loxP/þ mice did not develop renal cysts, indicating that loss of both copies of Tsc1 was necessary for inducing cyst formation. In addition, we found elevated P-S6 signal in cyst-lining cells in the double mutant kidney as PKD developed, in contrast to no obvious elevated P-S6 signal in control and Nse-cre;Pten loxP/loxP ;Tsc1 loxP/þ kidneys (Fig. 9B) . This, along with the observation in Tsc1 mutants, suggests that PKD development is closely related to mTORC1 activity. However, we did observe more severe PKD development in the double knockout mice, compared with the Tsc1 single knockout mice (data not shown); therefore, it is possible that Pten loss in addition to Tsc1 ablation in renal tubular cells accelerates cyst development through activation of other PTEN downstream pathways. Nevertheless, our data indicate that Pten loss alone is not sufficient to induce PKD due to limited activation of mTORC1 during early postnatal stages, indicating that PTEN is not a major upstream regulator of the TSC/mTORC1 pathway in this particular situation.
DISCUSSION
In the current study, we generated a mouse model of PKD by conditionally ablating the Tsc1 gene in a subset of renal tubular cells. Despite Cre-mediated recombination in the Figure 7 . Rapamycin treatment inhibits cyst formation and controls cyst development. (A) H&E staining reveals that acute rapamycin treatment effectively prevents cyst formation when applied during the early stages of cystogenesis. Control and Tsc1 mutant mice were treated with either vehicle or 2 mg/kg rapamycin at P7 and examined at P14. Scale bar, 2 mm for upper panels and 100 mm for lower panels. (B) Rapamycin injection controls cyst development when applied in later stages of cyst formation. Control and Tsc1 mutant mice were treated with either vehicle or 2 mg/kg rapamycin at P14 boosted once at P14 and examined at P28. Scale bar, 2 mm for upper panels and 100 mm for lower panels. (C, D) Rapamycin injections effectively reduce kidney enlargement in Tsc1 mutants in both groups as reflected by kidney weight, but do not affect normal growth of the mice. (E) Rapamycin injections reduce BUN levels in Tsc1 mutant mice. n ¼ 10 mice per group. Data are plotted by mean + SEM and analyzed by Student's t-test. Ã P , 0.05, ÃÃ P , 0.01 and ÃÃÃ P , 0.001 as compared with littermate controls or between groups as indicated.
kidney during early embryonic stages, there are no obvious embryonic abnormalities and signs of prenatal cyst formation. However, cystogenesis in Tsc1 mutants begins and rapidly develops postnatally, eventually resulting in premature death. This phenotype resembles the severe infantile PKD cases in humans caused by deletions of the contiguous TSC2 and PKD1 genes, demonstrating essential contribution of mTORC1 signaling to the etiology of this contiguous deletion syndrome.
The TSC/mTORC1 pathway is active in normal kidney development and attenuated thereafter as the kidney begins to mature. This results in an obvious reduction of P-S6 in the cortex of control kidney at P14, compared with P7 (Fig. 3A) . In addition, at P7, the initial cysts were observed only in the inner cortex, where P-S6 level is low in the normal kidneys, but remains high in the mutants due to loss of Tsc1. This might explain the postnatal appearance of cysts, despite the early embryonic expression of Nse-cre. Apparently, as the kidney develops, mTORC1 activity is gradually suppressed and this suppression may be necessary for normal renal tubular cell function. However, this normal down-regulation of mTORC1 activity is impaired in our mouse model following Tsc1 loss, which may lead to cyst formation. Tsc1 þ/2 mice and Eker rats are prone to developing isolated renal cysts, but usually do not develop severe polycystic kidneys (27 -31) . Here, we show that loss of Tsc1 starting from embryonic stages, in a subset of renal tubular cells, is sufficient to induce PKD. Consistent with our findings, some Eker rats develop PKD and presumably this is the result of loss of heterozygosity at the Tsc2 locus during early embryogenesis (32) . From the present study, we speculate that there may be a critical window for cyst expansion in kidney development. Other recent models of PKD have parallels to our data and collectively support this notion. It was recently reported that loss of Pkd1 in mice before postnatal day 13 results in severely cystic kidneys within 3 weeks, whereas inactivation at day 14 and later results in cyst appearance only after 5 months (33) . In addition, inactivation of the ciliogenic gene Kif3a in the kidney of newborn mice results in rapid cyst development, whereas inactivation of Kif3a in adult mice does not (34) . The finding that Pten ablation in the same embryonic kidney cells did not cause PKD was intriguing. In previous studies using the same Nse-cre;Pten loxp/loxp mutant mice, we demonstrated that loss of Pten in post-mitotic neurons in brain substantially elevated mTORC1 activity, and was accompanied by the appearance of neuronal hypertrophy (35) . Furthermore, the neuronal hypertrophy that developed in Pten mutant mice could be mimicked by mutation of Tsc1 and effectively suppressed by rapamycin administration (23) . Thus, in CNS neurons, TSC/mTORC1 is a major downstream effector of the PI3K/PTEN/AKT pathway that controls neuronal cell size. This is consistent with the fact that many PTEN-associated human diseases, such as Cowden's disease, Lhermitte-Duclos disease and Bannayan-Zonana syndrome, demonstrate phenotypes that overlap with the hamartoma syndrome seen in TSC patients. In contrast, in the kidney, loss of Pten did not phenocopy Tsc1 loss, although Pten and Tsc1 double mutant mice had a phenotype similar to, albeit somewhat stronger than, Tsc1 mutant mice. Thus, PTEN is not a major upstream regulator of TSC/mTORC1 in this context.
On the other hand, the relationship between TSC and polycystin proteins remains an open question. Our data suggest that activation of mTORC1 is sufficient to induce PKD, which supports the hypothesis proposed by Weimbs and colleagues that mTORC1 signaling is downstream of polycystin proteins and mediates PKD development (20) . In support of this, a recent study by Distefano et al. (36) reveals that Polycystin-1 regulates ERK-dependent phosphorylation of Tuberin to control cell size through mTORC1 in cultured cells. However, we cannot exclude other possibilities. The lack of reliable polycystin protein antibodies for in vivo immunostaining prevents examination of the possible effects on polycystin proteins in Tsc1 mutant mice.
It is also worth mentioning a recent study demonstrating that loss of either Tsc1 or Tsc2 in cultured cells causes enhanced cilium formation and increased cilium length. This effect is thought to be mTORC1-independent, as it could not be abrogated by rapamycin administration (37) . In our system, we observed the presence of primary cilia in some cyst-lining cells and some showed increased cilium length compared with controls, which is consistent with the above in vitro study (Supplementary Material, Fig. S6 ). However, it was difficult to further quantify the cilia length on tissue sections. We therefore cannot exclude the possibility that cyst formation is partially due to malfunction of the cilia. Nonetheless, the fact that rapamycin could effectively inhibit cyst formation argues for a major role of mTORC1 in the cystogenesis observed in our mouse model. In addition, we observed activated mTORC1 among cyst-lining cells that apparently lack Cre activity. This apparent non-cell autonomous effect resulted in broad activation of mTORC1 after Tsc1 loss in a subset of renal tubular cells, and therefore might also contribute to the rapid cyst development. We suspect that the elevated mTORC1 activation in the crenegative cyst-lining cells could be induced either directly by dysfunction of Tsc1-null cells or indirectly by cyst formation. This could be due to a paracrine effect or the consequence of cyst expansion. The exact mechanism(s) mediating this non-cell autonomous effect is not clear and will require further investigation.
MATERIALS AND METHODS
Mice breeding
Nse-cre mice were generated in Dr Suzanne J. Baker's lab (St. Jude Children's Research Hospital, Memphis, USA) and characterized in our lab (21) . To evaluate cre expression in the kidney, Nse-cre mice were crossed to either Rosa-stop-lacZ (25) 
BUN measurement
The whole blood of mice was collected and kept at RT for 30 -45 min before centrifugation. Serum was isolated by spinning the whole blood samples at 4000g for 3 min. Serum samples were then submitted to the mouse metabolic phenotyping core for BUN measurement by VITROS MicroSlide TM technology (U.T. Southwestern Medical Center).
X-gal staining
To collect tissues for X-gal staining, embryos or kidneys were harvested and fixed with 2% PFA overnight before cryopreservation in 30% sucrose and embedded in OCT. Cryostat sections were cut with 12-mm thickness and stained at 378C overnight and then counterstained with nuclear fast red as described previously (21) .
Ab and lectin staining
To prepare tissues for immunostaining, mice were perfused with PBS followed by 4% PFA. For BrdU staining, mice were injected with BrdU intraperitoneally (i.p.) 2 h before perfusion. Both thin paraffin sections (5-mm) and cryostat sections (6-mm) were used in the study. Triplicate sections with comparable anatomy were chosen from controls and mutants. Antibodies used for IHC were against LTA (Vector Labs, 1:1000), THP (Biomedical Technologies, 1:300), DBA (Vector Labs, 1:200) and AQP2 (Calbiochem, 1:400), BrdU (Dako, 1:500), Ki67 (Vector Labs, 1:2000), GFP that crossreacts with YFP (Aves Labs, 1:500) or P-S6 (Cell Signaling, 1:200). For paraffin sections, we used microwave antigen retrieval for all antibodies. For DAB staining, we visualized the primary antibodies by treating the sections with biotinylated secondary antibody followed by amplification with peroxidase-conjugated avidin and DAB substrate (Vector Labs, 1:200). DAB-stained sections were counterstained with hematoxylin. For immunofluorescent staining, we detected the primary antibodies by secondary antibodies conjugated with Cy3 or Cy2 (Jackson Immunoresearch, 1:200).
Western blotting
Kidneys were isolated and snap frozen in liquid nitrogen. To prepare the lysate, frozen kidneys were homogenized in lysis buffer containing 20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, proteinase inhibitor (Roche), Ser/Thr phosphatase inhibitor and Tyr phosphatase inhibitor (Upstate). Homogenate was centrifuged at 16 000 g for 30 min and supernatant was collected. Protein concentration was determined using a BCA kit (Pierce). For western blotting, 40 mg of sample was loaded onto an SDS-PAGE gel. Antibodies used for western blotting were against P-4EBP1 (Thr37/46) (Cell Signaling, 1:1000), 4EBP1 (Cell Signaling, 1:1000), P-S6 (Ser235/236) (Cell Signaling, 1:1000), S6 (Cell Signaling, 1:1000), PTEN (Cell Signaling, 1:1000), P-AKT (Ser473) (Cell Signaling, 1:1000), AKT (Cell Signaling, 1:1000), a-tubulin (Sigma, 2000) or b-actin (Sigma, 1:5000). Signal was developed by ChemiGlow West reagent (Alpha Innotech) and visualized using a Kodak Image Station 2000R (Rochester).
Rapamycin injection
Rapamycin powder (Sirolimus, LC Laboratories) was dissolved in ethanol and stored at a stock concentration of 25 mg/ml in aliquots at 2208C. Working solution was prepared freshly before use with a final concentration of 0.1 mg/ml rapamycin in 4% ethanol, 5% Tween 80 and 5% PEG400. Mice were injected i.p. with either rapamycin (2 mg/kg body weight) or vehicle.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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